 In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the aggregate number of common shares plus the common shares underlying the pre-funded warrants in the offering on the same terms and conditions. All of the common shares and pre-funded warrants are being offered by Axovant. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SECs website, located at 